Various uses of mifepristone in gynaecology and obstetrics

References

• J.H. Liu, S.S.C. Yen. Induction of midcycle gonadotropin surge by ovarian steroids in women: a critical evaluation. Journal of Clinical Endocrinology and Metabolism. 57: 1983; 797–802.
   PubMed Web of Science ®Google Scholar
• J.H. Liu, G. Garzo, S. Morris. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU 486. Journal of Clinical Endocrinology and Metabolism. 65: 1987; 1135–1140.
   PubMed Web of Science ®Google Scholar
• D. Shoupe, D.R. Mishell, M.A. Page. Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. American Journal of Obstetrics and Gynecology. 157: 1987; 1421–1426.
   PubMed Web of Science ®Google Scholar
• M.L. Swahn, E. Johannisson, V. Daniore. The effect of RU 486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium. Human Reproduction. 3: 1988; 915–921.
   PubMed Web of Science ®Google Scholar
• G. Schaison, M. George, N. Lestrat. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women. Journal of Clinical Endocrinology and Metabolism. 61: 1985; 484–489.
   PubMed Web of Science ®Google Scholar
• V.G. Garzo, J. Liu, A. Ulmann. Effects of an antiprogesterone (RU 486) on the hypothalamic-hypophysealovarian-endometrial axis during the luteal phase of the menstrual cycle. Journal of Clinical Endocrinology and Metabolism. 66: 1988; 508–517.
   PubMed Web of Science ®Google Scholar
• M.L. Swahn, M. Bygdeman, S. Xing. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Human Reproduction.. 5: 1990; 402–408.
   PubMed Web of Science ®Google Scholar
• K.E. Green, L.M. Kettel, S.S.C. Yen. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential Fertility and Sterility. 58: 1993; 338–343.
   Google Scholar
• M.C. Batista, T.P. Cartledge, A.W. Zellmer. Delayed endometrial maturation by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy. American Journal of Obstetrics and Gynecology. 67: 1992; 60–65.
   Google Scholar
• K. Gemzell Danielsson, P. Svalander, M.L. Swahn. Effects of a single post-ovulatory dose of RU 486 on endometrial maturation in the implantation phase. Human Reproduction.. 9: 1994; 2398–2404.
   PubMed Web of Science ®Google Scholar
• A. Rådestad, N.J. Christensen, L. Strömberg. Induced cervical ripening with mifepristone in first trimester abortion. A double-blind randomized biomechanical study. Contraception. 38: 1988; 301–312.
   PubMed Web of Science ®Google Scholar
• M.L. Swahn, M. Bygdeman. The effect of antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandins and oxytocin. British Journal of Obstetrics and Gynaecology. 95: 1988; 126–134.
   PubMedGoogle Scholar
• L. Kovacs, M. Sas, B.A. Resch. Termination of very early pregnancy by RU 486 - an antiprogestational compound. Contraception. 29: 1984; 399–410.
   PubMed Web of Science ®Google Scholar
• W.L. Herrman, A.M. Schindler, R. Wyss. Effects of the antiprogesterone RU 486 in early pregnancy and during the menstrual cycle. E.E. Baulieu, S.J. Segal. The Antiprogestin Steroid RU 486 and Human Fertility Control. 1985; Plenum Press: New York.
   Google Scholar
• L. Birgerson, V. Odlind. Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and epostane. Fertility and Sterility. 48: 1987; 565–570.
   PubMed Web of Science ®Google Scholar
• A. Ulmann. Uses of RU 486 for contragestion: an update. Contraception. 36: 1987; 27–31. (suppl.).
   PubMedGoogle Scholar
• M. Bygdeman, M.L. Swahn. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception. 32: 1985; 45–51.
   PubMed Web of Science ®Google Scholar
• For references see. M. Bygdeman. Termination of pregnancy up to 8 or 9 weeks. D. Grimes, P.F.A. Van Look. Modern Methods of inducing Abortion. 1995; Blackwell Science: Oxford.
   Google Scholar
• K.J. Thong, D.T. Baird. Induction of abortion with mifepristone and misoprostol in early pregnancy. British Journal of Obstetrics and Gynaecology. 99: 1992; 1004–1007.
   PubMedGoogle Scholar
• R. Peyron, E. Aubeny, V. Targosz. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. New England Journal of Medicine. 328: 1993; 1509–1513.
   PubMed Web of Science ®Google Scholar
• C. McKinley, K.J. Thong, D.T. Baird. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Human Reproduction. 8: 1993; 1502–1505.
   PubMed Web of Science ®Google Scholar
• Y.F. Chan, P.C. Ho, H.K. Ma. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception. 47: 1993; 85–95.
   PubMed Web of Science ®Google Scholar
• A. Ulmann, L. Silvestre, L. Chemama. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue; Study in 16,369 women. Acta Obstetricia et Gynecologica Scandinavica. 71: 1992; 278–283.
   PubMed Web of Science ®Google Scholar
• D.T. Baird, N. Sukchroen, K.J. Thong. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Human Reproduction. 10: 1995; 1521–1527.
   PubMed Web of Science ®Google Scholar
• K. Hilmgren. Women's evaluation of three early abortion methods. Acta Obstetricia et Gynecologica Scandinavica. 71: 1992; 616–623.
   Web of Science ®Google Scholar
• For review see. M. Bygdeman. Non-invasive methods for termination of second trimester pregnancy. M. Bygdeman. Clinical Obstetrics and Gynaecology: Medical Induction of Abortion. 1990; Baillière Tindall: London.
   Google Scholar
• D.R. Urquhart, C. Bahzar, A.A. Templeton. Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy. Human Reproduction. 4: 1989; 202–203.
   Web of Science ®Google Scholar
• M.W. Rodger, D.T. Baird. Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. British Journal of Obstetrics and Gynaecology. 97: 1990; 41–45.
   PubMedGoogle Scholar
• C. Gottlieb, M. Bygdeman. The use of antiprogestin (RU 486) for termination of second trimester pregnancy. Acta Obstetricia et Gynecologica Scandinavica. 70: 1991; 199–203.
   PubMed Web of Science ®Google Scholar
• K.J. Thong, D.T. Baird. Induction of second trimester abortion with mifepristone and gemeprost. British Journal of Obstetrics and Gynaecology. 100: 1993; 758–761.
   PubMedGoogle Scholar
• P.C. Ho, H.K. Ma. Termination of second trimester pregnancy with sulprostone and mifepristone: A randomized double-blind placebo-controlled trial. Contraception. 47: 1993; 123–129.
   PubMed Web of Science ®Google Scholar
• D. Cabrol, M. Bouvier d'Yvoire. Induction of labour with mifepristone after intrauterine fetal death. Lancet. ii: 1985; 1019.
   Google Scholar
• R. Frydman, C. Lelaider, C. Baton-Saint-Mieur. Labour induction in women at term with mifepristone (RU 486): A doubleblind, randomized, placebocontrolled study. Obstetrics and Gynecology. 80: 1992; 972–975.
   Google Scholar
• N.C.W. Hill, M. Selinger, J. Ferguson. Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy. Human Reproduction. 6: 1991; 458–462.
   Web of Science ®Google Scholar
• W.L. Ledger, V.M. Sweeting, H. Hillier. Inhibition of ovulation by low-dose mifepristone (RU 486). Human Reproduction. 7: 1992; 945–950.
   PubMed Web of Science ®Google Scholar
• S.C.C. Yen. Use of antiprogestin in the management of endometriosis and leiomyoma. M.S. Donaldson, L. Dorflinger, S.B. Brown, L.Z. Benet. Clinical Applications of Mifepristone and Other Antiprogestins. 1993; National Academy Press: Washington.
   Google Scholar
• S.W.J. Lamberts, J.W. Koper, F.H. de Jong. The endocrine effects of long-term treatment with mifepristone (RU 486). Journal of Clinical Endocrinology and Metabolism. 73: 1991; 187–191.
   PubMed Web of Science ®Google Scholar
• As proposed by. R. Kekkonen, H. Alfthan, M. Haukkamaa. Interference with ovulation by sequential treatment with the antiprogesterone RU 486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation. Human Reproduction. 10: 1995; 287–292.
   PubMed Web of Science ®Google Scholar
• K. Gemzell Danielsson, M.L. Swahn, P. Svalander. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Human Reproduction. 8: 1993; 870–873.
   PubMed Web of Science ®Google Scholar
• A. Glasier, K.J. Thong, M. Dewar. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. New England Journal of Medicine. 327: 1992; 1041–1044.
   PubMed Web of Science ®Google Scholar
• A.M.C. Webb, J. Russell, M. Elstein. Comparison of Yuzpe regimen, danazol and mifepristone (RU 486) in oral postcoital contraception. British Medical Journal. 305: 1992; 927–931.
   PubMed Web of Science ®Google Scholar
• H.B. Croxatto, A.M. Salvatierra, H.D. Croxatto. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Human Reproduction. 8: 1993; 201–207.
   PubMed Web of Science ®Google Scholar
• I.M. Spitz, H.B. Croxatto, A.M. Salvatierra. Response to intermittent RU 486 in the women. Fertility and Sterility. 59: 1993; 971–975.
   PubMed Web of Science ®Google Scholar
• K. Gemzell Danielsson, P. Westlund, M.L. Swahn. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Human Reproduction. 11: 1996; 256–264.
   PubMed Web of Science ®Google Scholar
• A.A. Murphy, L.M. Kettel, A.J. Morales. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. Journal of Clinical Endocrinology and Metabolism. 76: 1993; 513–517.
   PubMed Web of Science ®Google Scholar
• L.M. Kettel, A.A. Murphy, J.F. Mortola. Endocrine responses to long-term administration of the antiprogesterone RU 486 in patients with pelvic endometriosis. Fertility and Sterility. 56: 1991; 402–407.
   PubMed Web of Science ®Google Scholar
• J.F.H.M. van Uem, J.G. Hsiu, C.F. Chillik. Contraceptive potential of RU 486 by ovulation inhibition: Pituitary versus ovarian action with blockade of estrogen induced endometrial proliferation. Contraception. 40: 1989; 171–184.
   Web of Science ®Google Scholar
• S. Bardon, F. Vignon, D. Chalbos. RU 486, a progestin and glucocorticoid antagonist inhibits the growth of breast cancer cells via the progesterone receptor. Journal of Clinical Endocrinology and Metabolism. 60: 1985; 692–697.
   PubMed Web of Science ®Google Scholar
• G. Romieu, T. Maudelonde, A. Ulmann. The antiprogestin RU 486 in advanced breast cancer: Preliminary clinical trial. Bulletin du Cancer. 74: 1987; 455–461.
   PubMed Web of Science ®Google Scholar
• G.H. Bakker, B. Setyono-Han, H. Portengen. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. Journal of Steroid Biochemistry and Molecular Biology. 37: 1990; 789–794.
   PubMed Web of Science ®Google Scholar